Relebactam is a small novel non-β-lactam inhibitor molecule structurally related to avibactam . It is combined with imipenem-cilastatin to form a β-lactam-β-lactamase inhibitor combination.
Recarbrio (imipenem/cilastatin/relebactam) (Fig. 4) was approved by the US FDA for the treatment of adults with HABP/VABP in 2019.
河北唯特醫(yī)藥科技有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!
河北唯特醫(yī)藥